Viking Therapeutics VKTX is set to report third-quarter 2026 earnings on Oct. 28, after market close. Because the company has no marketed drugs in its portfolio, it is not expected to record revenue. The Zacks Consensus Estimate pegs earnings at a loss of $1 per share. Loss estimates for 2026 have slightly improved from $4.47 to $4.46 per share over the past 30 days. However, those for 2027 have remained unchanged at a loss of $4.08 over the same period.Zacks Investment Research Image Source: Zacks Investment Research VKTX's Earnings Surprise History Earnings missed estimates in three of the trailing four quarters and beat the mark on one occasion, delivering a negative average surprise of 26.47%.
Wir zeigen den wichtigsten Punkt oeffentlich. Erstellen Sie ein kostenloses Konto, um den vollstaendigen Artikel zu lesen, ihn zu speichern, zu diskutieren und mit Markt- und OSINT-Kontext zu verbinden.